Compare ARL & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARL | CGEN |
|---|---|---|
| Founded | 1999 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.9M | 188.2M |
| IPO Year | 1999 | 2001 |
| Metric | ARL | CGEN |
|---|---|---|
| Price | $14.50 | $3.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 1.9K | ★ 398.6K |
| Earning Date | 05-08-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 206.59 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $50,014,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | $15.02 | ★ N/A |
| Revenue Growth | ★ 5.70 | N/A |
| 52 Week Low | $11.29 | $1.23 |
| 52 Week High | $20.00 | $2.99 |
| Indicator | ARL | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 79.18 |
| Support Level | $13.66 | $1.45 |
| Resistance Level | $15.95 | N/A |
| Average True Range (ATR) | 0.45 | 0.18 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 51.24 | 88.57 |
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments: the acquisition, development, ownership and management of multifamily properties (Residential Segment) and the acquisition, ownership and management of commercial real estate properties (Commercial Segment). Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.